Generali Investments Management Co LLC Has $2.80 Million Holdings in Johnson & Johnson $JNJ

Generali Investments Management Co LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 14.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,347 shares of the company’s stock after selling 3,183 shares during the quarter. Generali Investments Management Co LLC’s holdings in Johnson & Johnson were worth $2,799,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of JNJ. GFG Capital LLC bought a new stake in Johnson & Johnson in the 2nd quarter valued at approximately $35,000. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson in the first quarter worth $48,000. Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson during the first quarter worth $52,000. Finally, Pandora Wealth Inc. bought a new position in Johnson & Johnson in the first quarter valued at $65,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JNJ has been the subject of a number of recent research reports. Stifel Nicolaus increased their price objective on shares of Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a research note on Wednesday, October 15th. Morgan Stanley set a $190.00 price target on Johnson & Johnson in a research report on Wednesday, October 15th. Loop Capital set a $190.00 price target on Johnson & Johnson in a research note on Wednesday, October 22nd. Scotiabank initiated coverage on Johnson & Johnson in a research note on Thursday. They set a “sector outperform” rating and a $230.00 price objective on the stock. Finally, JPMorgan Chase & Co. raised their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Tuesday, September 16th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $201.05.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Up 0.4%

JNJ opened at $196.00 on Friday. The stock’s fifty day simple moving average is $185.81 and its 200 day simple moving average is $170.04. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $197.18. The stock has a market cap of $472.22 billion, a PE ratio of 18.92, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. As a group, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.